Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Innovent Adds Second ADC to Collaboration with Synaffix, an ADC CRO

publication date: Dec 7, 2023

Suzhou Innovent Biologics will expand its partnership with Synaffix, a Lonza company (SIX:LONN), using the company’s technology to develop at least one antibody-drug conjugate (ADC) candidate. In 2021, Innovent employed Synaffix's ADC technologies to develop IBI343, a CLDN18.2 ADC, which is now in a Phase 1 trial. Innovent will be responsible for all development for the new new ADC candidates, while Synaffix is eligible to receive an upfront payment plus potential milestones and royalties on commercial sales for each licensed target. Details were not disclosed. Earlier this year, Lonza paid 100 million euros to acquire Synaffix, an Amsterdam company. More details....

Stock Symbol: (HK: 01801)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here